2018
DOI: 10.1007/s10620-017-4900-8
|View full text |Cite
|
Sign up to set email alerts
|

Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
5
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 11 publications
0
5
0
Order By: Relevance
“…A case report of a patient with Child Pugh A cirrhosis due to PBC who developed clinical and histologic cholestatic hepatitis two months after stopping a higher than recommended dose of ursodeoxycholic acid (23mg/kg) and simultaneously starting obeticholic acid has recently been reported . The authors of this article postulated that this event was triggered by an increase in hydrophobic bile acids in addition to a reduction in bile flow, leading to cholestatic hepatitis. In the phase 2 obeticholic acid study in patients with PBC and an inadequate response to ursodeoxycholic acid, Hirschfield and colleagues reported jaundice in two patients .…”
Section: Obeticholic Acid and Potential Hepatotoxicitymentioning
confidence: 99%
“…A case report of a patient with Child Pugh A cirrhosis due to PBC who developed clinical and histologic cholestatic hepatitis two months after stopping a higher than recommended dose of ursodeoxycholic acid (23mg/kg) and simultaneously starting obeticholic acid has recently been reported . The authors of this article postulated that this event was triggered by an increase in hydrophobic bile acids in addition to a reduction in bile flow, leading to cholestatic hepatitis. In the phase 2 obeticholic acid study in patients with PBC and an inadequate response to ursodeoxycholic acid, Hirschfield and colleagues reported jaundice in two patients .…”
Section: Obeticholic Acid and Potential Hepatotoxicitymentioning
confidence: 99%
“…We have reviewed Dr. Feng’s clarification submitted in response to our recent publication in Digestive Diseases and Sciences regarding the use of Obeticholic acid (OCA) among Primary Biliary Cholangitis (PBC) patients with or without decompensated liver disease [ 4 ]. It is indeed important to disseminate this information and keep the physicians abreast of how best to use OCA, particularly in the context of recently released Food and Drug Authority (FDA) reports associating morbidity and mortality among PBC patients with OCA therapy [ 5 ].…”
mentioning
confidence: 99%
“…At least in our own anecdotal experience in a patient with compensated cirrhosis, jaundice did not occur due to idiosyncratic or dose dependent OCA toxicity but was found to be possibly related to an abrupt withdrawal of UDCA [ 4 ]. Withdrawal of UDCA was not done voluntarily but occurred fortuitously, which unfortunately can occur in doctors’ offices where medication errors are not infrequent [ 8 ].…”
mentioning
confidence: 99%
See 2 more Smart Citations